Phase II trial of 5-FU, vincristine, and mitomycin (FoMi) in metastatic bronchioloalveolar cell lung cancer: A southwest oncology group study

Research output: Contribution to journalArticle

3 Scopus citations

Abstract

Twenty-three previously untreated patients with bronchioloalveolar cell lung cancer who had measurable disease and distant metastases (stage IIIM1, extensive) were treated with combination chemotherapy including 5-FU, vincristine, and mitomycin. Two of 23 patients (9%) achieved partial response lasting 5 and 6 months. Two patients (9%) died of sepsis while neutropenic. The current study does not justify the use of 5-FU, vincristine, and mitomycin combination chemotherapy in patients with metastatic bronchioloalveolar cell lung cancer.

Original languageEnglish (US)
Pages (from-to)1313-1314
Number of pages2
JournalCancer Treatment Reports
Volume69
Issue number11
StatePublished - Dec 1 1985

ASJC Scopus subject areas

  • Oncology
  • Cancer Research

Fingerprint Dive into the research topics of 'Phase II trial of 5-FU, vincristine, and mitomycin (FoMi) in metastatic bronchioloalveolar cell lung cancer: A southwest oncology group study'. Together they form a unique fingerprint.

  • Cite this